

IC14 Rec'd PCT/PTO 02 JAN

Atty. Dkt. No. 053466-0299

ED STATES PATENT AND TRADEMARK OFFICE

Applicant:

Akihiro FUNAKOSHI et al.

Title:

A PREVENTIVE OR

THERAPEUTIC AGENT FOR

PANCREATITIS COMPRISING IL-6 ANTAGONIST AS AN ACTIVE

**INGREDIENT** 

**RECEIVED** 

JUN 0 7 2002

TECH CENTER 1600/2900

Appl. No.:

09/762,550

Filing Date: 02/09/2001

Examiner:

M. Kirk

Art Unit:

1651

### REQUEST FOR CORRECTED FILING RECEIPT

Commissioner for Patents Washington, D.C. 20231

Sir:

It is respectfully requested that a corrected Filing Receipt be issued in connection with the above-identified application in order to correct typographical error in the listing of the foreign application date.

In the line Foreign Applications:

Kindly change:

[JAPAN 11-054302 02/02/1999]

To:

JAPAN 11-054302 03/02/1999

A copy of the Filing Receipt and a copy of the Declaration and Power of Attorney (where upon the date for the prior foreign application is correctly listed) is enclosed.

Should no proper payment be enclosed herewith, as by a check being in the wrong amount, unsigned, post-dated, otherwise improper or informal or even entirely missing, the Commissioner is authorized to charge the unpaid amount to Deposit Account No. 19-0741.

Kindly forward a corrected Filing Receipt to the undersigned attorney of record as soon as possible.

Respectfully submitted,

Mieu a D. Kan

Date January 2, 2002

FOLEY & LARDNER
Washington Harbour
3000 K Street, N.W., Suite 500
Washington, D.C. 20007-5143
Telephone: (202) 672-5571

Facsimile: (202) 672-5399

Harold C. Wegner Attorney for Applicant Registration No. 25,258



## UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, D.C. 2023I
www.uspto.gov

FILING DATE **GRP ART UNIT** FIL FEE REC'D ATTY.DOCKET.NO. **DRAWINGS TOT CLAIMS** IND CLAIMS APPLICATION NUMBER 1651 1208 053466/0299 09/762,550 02/09/2001 4 26 6

JAN 0'2 2002

**CONFIRMATION NO. 5276** 

23533 STEPHEN B MAEBIUS FOLEY AND LARDNER 3000 K STREET N W SUITE 500 WASHINGTON, DC 20007-5109 FILING RECEIPT

\*OC000000006008203\*

Date Mailed: 04/25/2001

Receipt is acknowledged of this nonprovisional Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Customer Service Center. Please provide a copy of this Filing Receipt with the changes noted thereon. If y u received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s)

Akihiro Funakoshi, Fukuoka, JAPAN; Kyoko Miyasaka, Tokyo, JAPAN;

Domestic Priority data as claimed by applicant

THIS APPLICATION IS A 371 OF PCT/JP99/04533 08/23/1999

Foreign Applications

JAPAN 10-251796 08/24/1998 JAPAN 11-054302 <del>02/02/1</del>999\_

03/02/1999

Projected Publication Date: N/A

Non-Publication Request: No


Early Publication Request: No

Title

Preventives or remedies for pancreatitis containing il-6 antagonists as the active ingredient

**Preliminary Class** 

435







# LICENSE FOR FOREIGN FILING UNDER Title 35, United States Code, Section 184

Title 37, Code of Federal Regulations, 5.11 & 5.15

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a cense have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

#### **NOT GRANTED**

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).

### PLEASE NOTE the following information about the Filing Receipt:

- The articles such as "a," "an" and "the" are not included as the first words in the title of an application. They are considered to be unnecessary to the understanding of the title.
- The words "new," "improved," "improvements in" or "relating to" are not included as first words in the title of an application because a patent application, by nature, is a new idea or improvement.
- The title may be truncated if it consists of more than 500 characters (letters and spaces combined).
- The docket number allows a maximum of 25 characters.
- If your application was submitted under 37 CFR 1.10, your filing date should be the "date in" found on the Express Mail label. If there is a discrepancy, you should submit a request for a corrected Filing Receipt along with a copy of the Express Mail label showing the "date in."
- The title is recorded in sentence case.

Any corrections that may need to be done to your Filing Receipt should be directed to:

Assistant Commissioner for Patents
Office of Initial Patent Examination
Customer Service Center
Washington, DC 20231